Alnylam Pharmaceuticals Inc. (ALNY) Downgraded by Barclays PLC to “Equal Weight”
Barclays PLC cut shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) from an overweight rating to an equal weight rating in a research report released on Thursday. Barclays PLC currently has $50.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $85.00.
Several other research firms have also recently issued reports on ALNY. Jefferies Group reiterated a buy rating and issued a $80.00 target price (down from $119.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, June 8th. Zacks Investment Research lowered shares of Alnylam Pharmaceuticals from a hold rating to a sell rating in a report on Monday, July 25th. FBR & Co reissued an outperform rating and issued a $180.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, September 27th. Morgan Stanley set a $93.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, September 6th. Finally, Chardan Capital reissued a buy rating on shares of Alnylam Pharmaceuticals in a report on Monday, July 11th. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $85.75.
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 4.64% during trading on Thursday, reaching $34.53. 2,648,519 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a one year low of $34.18 and a one year high of $110.75. The company has a 50-day moving average price of $71.80 and a 200 day moving average price of $66.24. The firm’s market capitalization is $2.96 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The firm earned $8.70 million during the quarter, compared to analysts’ expectations of $8.09 million. During the same period in the previous year, the business posted ($0.85) EPS. The business’s revenue was up .2% compared to the same quarter last year. On average, analysts anticipate that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current fiscal year.
In related news, CEO John Maraganore sold 30,151 shares of the company’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.00% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the stock. Dodge & Cox purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $139,650,000. Wellington Management Group LLP raised its stake in shares of Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock worth $749,826,000 after buying an additional 1,288,123 shares in the last quarter. Bridger Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $50,041,000. Slate Path Capital LP raised its stake in shares of Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock worth $71,244,000 after buying an additional 410,000 shares in the last quarter. Finally, Deerfield Management Co. purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $18,645,000. 85.96% of the stock is owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.